Compare DexCom, Inc. (DXCM) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MINISO Group Holding Ltd — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while MINISO Group Holding Ltd trades at $13.09 (market cap $3.73B). The key difference: DexCom, Inc. is far larger — about 7.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.28% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MNSO | |
|---|---|---|
Market Cap | $28.06B | $3.73B |
Sector | Health | Technology |
52-Week High | $89.53 | $26.63 |
52-Week Low | $54.84 | $11.30 |
Enterprise Value | $27.03B | $4.39B |
Dividend Yield | — | 5.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
MNSO trades at $13.09, up 13.53% today, reflecting strong momentum. The stock shows bullish technical signals with support near $12 and resistance at $13. Fundamentally, Q1 2026 earnings beat expectations with EPS of $0.591, while revenue grew 28.5% year-over-year. The company announced a HK$2 billion share repurchase program in June 2026, signaling confidence in its value. Valuation ratios remain attractive with a P/E of 12.84 and P/S of 1.16.
Outlook is positive given earnings growth and shareholder-friendly actions, but risks include margin pressure from rising expenses and geopolitical factors affecting its global operations. Analyst consensus leans bullish with 75% buy ratings, supporting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
